Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

e II trial and another milestone upon the dosing of the first patient in a Phase III trial for any use of the drug.

Myriad also reported data from two completed Phase 1 clinical trials of Azixa in a total of 66 patients, one in patients with refractory solid tumors that may also have had brain metastases and the other in patients with known brain metastases. The trials were designed to explore the safety and pharmacokinetics of Azixa and to find the maximum tolerated dose of the compound. Myriad reported that in the Phase 1 studies, Azixa appeared to have a biological effect on patients' metastases from many different primary tumors, including non-small-cell lung cancer, which is consistent with the mechanism of the drug candidate.

Azixa is one of two compounds in clinical trials discovered through EpiCept's Anti-cancer Screening Apoptosis Program (ASAP). EPC2407, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of cancer patients with advanced, solid tumors and lymphomas, is currently in Phase I clinical development by EpiCept. In July 2007, EpiCept announced the acceleration of the Phase I clinical trial, with results expected later this year. EpiCept expects to initiate a second Phase I efficacy trial for EPC2407 as a combination therapy in patients with well vascularized solid tumors and intends to choose multiple tumor targets for the compound's Phase II trials as the clinical profile from the ongoing monotherapy trial emerges.

About EpiCept's ASAP Technology

Cancer cells often exhibit unchecked growth caused by the disabling or absence of the natural process of programmed cell death, which is called apoptosis. Apoptosis is normally triggered to destroy a cell from within when it outlives its purpose or it is seriously damaged. One of the most promising approaches in the fight against cancer is to selectively induce apoptosis in cancer cells, thereby checking, and perhaps reversing, the improper ce
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3,  2015 About ... bio-artificial devices, which are implanted or integrated ... organs. These include artificial heart, kidney, pancreas, ... polymers (polyurethane, polysulfone, and porous polypropylene), biologics, ... artificial organs. These organs are incorporated with ...
(Date:9/3/2015)... 3, 2015 About dry eye syndrome Dry ... to deficient tear production or quick tear evaporation or ... types: aqueous tear deficient dry eye and evaporative dry ... do not produce enough tears, whereas meibomian gland dysfunction ... to slow tear evaporation and maintain tear stability. The ...
(Date:9/3/2015)... Sept. 3, 2015  Ascendis Pharma A/S ... biotechnology company that applies its innovative TransCon ... today announced plans to present at several ... Healthcare Conference in BostonDate: , Thursday, September ... of America Merrill Lynch Global Healthcare Conference ...
Breaking Medicine Technology:Global Artificial Organ Market 2015-2019 2Global Dry Eye Syndrome Market 2015-2019 2Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences 2
... WIRE)--May 21, 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today ... on the Company's prostate cancer drug candidate CB7630,(abiraterone ... Annual Meeting, which is currently taking place,in Anaheim, ... A.,Yap from the Cancer Research UK Centre for ...
... 40/12.5 and 40/25 mg/day and Amlodipine +,Benazepril ... Society of,Hypertension Twenty-Second Annual Scientific Meeting, PARSIPPANY, ... data,presented today at the American Society of ... Chicago,demonstrated that the fixed-dose combination Benicar HCT,(olmesartan ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8
(Date:9/4/2015)... ... September 04, 2015 , ... After wearing the same uniforms for six ... apparel. In an effort to assist the team, the Jones Agency, a locally owned ... to raise funds for the new uniforms. , As is so often the case ...
(Date:9/4/2015)... ... 04, 2015 , ... A Union County charitable organization will ... Project is a non-profit organization dedicated to offering Pilates scholarships to cancer patients ... and recover their mobility, strength, and range of motion following breast cancer surgery. ...
(Date:9/4/2015)... ... September 04, 2015 , ... Keeping mold top of mind is important ... quite common. Mold can grow anywhere - on carpet, clothing, food, paper, and even ... moisture and water in the home is key to preventing mold growth, which if ...
(Date:9/4/2015)... ... 2015 , ... “Getting away from the daily stressors and distractions of life ... their ‘couple-ness,’” says Jean Claude Wietzel, general manager at Four Seasons Resort Maui ... only Forbes Five Star resort and Travel + Leisure’s No. 1 Hotel in Hawaii, ...
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way to ... The patent-pending K Med Cups provide a quick and simple way to brew a hot ... flu or cough. As a result, they enhance comfort and health. The invention features a ...
Breaking Medicine News(10 mins):Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2
... Network Sciences, Inc. (GNS) today announced that it has ... of Connecticut Health Center,s Carole and Ray Neag ... genetic, genomic and clinical data ("3-D Data") together into ... identify the best treatments for individual patients and to ...
... OKLAHOMA CITY, June 3 OrthoCare Innovations is pleased ... Laboratory (APL) researchers Stuart Harshbarger, in the role of ... of Robotic Systems. , , (Photo: ... principal professional staff at APL, Mr. Harshbarger has served ...
... , BREVARD, N.C., June 3 Gaia Herbs, the Transylvania ... public to their 2nd annual Summer Solstice Open House, Saturday ... tours are being offered at the pristine 250-acre certified organic ... , , Visitors will have the opportunity to learn ...
... ... range of Renewable Energy Products on display at the show , ... (PRWEB) June 3, 2009 -- FCI-BURNDY® ... systems, grounding and tower applications, and wind farm projects. These products included the BURNDYWeld® ...
... ... PerformanceTest Services to validate the server capacity of their online applications with 100% realistic performance ... end-user experience -- without the need to invest in tools, people or training. , ... San Francisco, CA (PRWEB) June 3, ...
... ... services. , ... Jose, Calif. (PRWEB) June 3, 2009 -- The Glowan Consulting Group, a recognized leader ... store allowing clients and partners to purchase their suite of Leadership Assessment Products directly ...
Cached Medicine News:Health News:Gene Network Sciences Announces Cancer Collaboration with University of Connecticut Health Center's Neag Comprehensive Cancer Center 2Health News:Gene Network Sciences Announces Cancer Collaboration with University of Connecticut Health Center's Neag Comprehensive Cancer Center 3Health News:Johns Hopkins University Applied Physics Lab Group Joins OrthoCare Innovations 2Health News:Gaia Herbs Announces Annual Summer Solstice Open House 2Health News:FCI-BURNDY Products Wins "Best Of Trade Show" Award at Windpower 2009 Conference and Exhibition 2Health News:FCI-BURNDY Products Wins "Best Of Trade Show" Award at Windpower 2009 Conference and Exhibition 3Health News:Server Load PerformanceTest™ Breakthrough For AJAX Applications 2Health News:Server Load PerformanceTest™ Breakthrough For AJAX Applications 3Health News:Server Load PerformanceTest™ Breakthrough For AJAX Applications 4Health News:Server Load PerformanceTest™ Breakthrough For AJAX Applications 5Health News:Glowan Consulting Announces New On-Line E-Commerce Site 2
... II SP MRI-Compatible Anesthesia System is perfect for ... than one type of anesthetic agent. , ... due to its wider stance, has a larger ... bellows assembly is utilized in both the Integra ...
The very bright medical maginifier lamp for examination and labratory....
... Market leader in soft tissue repair in ... has developed the latest evolution in orthopedic ... ORTHOCORD Suture is as strong as any ... importantly, ORTHOCORD Suture handles like ETHIBOND®., ,ORTHOCORD ...
... The SuturTek 360Fascia Closure Deviceprotects ... suture needlesticks and the threat of ... suturing, while at the same time ... safely, quickly, and easily. The SuturTek ...
Medicine Products: